Compare MKTW & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKTW | SCLX |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 55.1M |
| IPO Year | 2020 | 2020 |
| Metric | MKTW | SCLX |
|---|---|---|
| Price | $18.50 | $5.41 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 15.9K | ★ 37.5K |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | ★ 10.20% | N/A |
| EPS Growth | ★ 1183.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $512,403,000.00 | $30,253,000.00 |
| Revenue This Year | $1.52 | $122.52 |
| Revenue Next Year | $4.55 | $186.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.49 | $4.20 |
| 52 Week High | $22.83 | $34.27 |
| Indicator | MKTW | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 33.73 |
| Support Level | $16.22 | $4.20 |
| Resistance Level | $21.40 | $7.77 |
| Average True Range (ATR) | 0.56 | 0.30 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 74.16 | 16.67 |
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.